Quick Answer
Aligos Therapeutics, Inc. reported Stockholders Equity of $53.55 million for fiscal year 2025.
Aligos Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $53.55M | +284.8% |
| 2024 | -$28.97M | -131.5% |
| 2023 | $92.08M | -11.4% |
| 2022 | $103.90M | -43.8% |
| 2021 | $184.73M | -16.0% |
| 2020 | $220.04M | +439.1% |
| 2019 | -$64.89M | -372.0% |
| 2018 | -$13.75M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $71.83M | +43.4% | -29.5% |
| June 30, 2025 | $101.87M | +51.5% | -12.5% |
| March 31, 2025 | $116.44M | +94.7% | +501.9% |
| December 31, 2024 | -$28.97M | -131.5% | -157.8% |
| September 30, 2024 | $50.10M | -8.6% | -25.5% |
| June 30, 2024 | $67.23M | -3.5% | +12.4% |
| March 31, 2024 | $59.80M | -29.4% | -35.1% |
| December 31, 2023 | $92.08M | -11.4% | +68.0% |
- Aligos Therapeutics, Inc. showed an increase of +284.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Aligos Therapeutics, Inc.’s stockholders equity has grown by 489.5% (from -$13.75 million to $53.55 million).
- The most recent figure is from Aligos Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: